^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    taselisib (GDC-0032)

    i
    Company:
    Roche
    Drug class:
    PI3Kα inhibitor
    Related drugs:
    Apply
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bicalutamide • leucovorin calcium • bendamustine • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer (NCT02390427)
    Phase 1
    Otto Metzger, MD
    Completed
    Last update posted :
    10/02/2024
    Initiation :
    04/20/2015
    Primary completion :
    12/01/2022
    Completion :
    07/01/2024
    HER-2
    |
    Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • taselisib (GDC-0032)
    Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) (NCT04439175)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/08/2024
    Initiation :
    02/25/2016
    Primary completion :
    11/10/2020
    Completion :
    03/07/2025
    PIK3CA
    |
    PIK3CA mutation
    |
    taselisib (GDC-0032)
    Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer (NCT02154490)
    Phase N/A
    SWOG Cancer Research Network
    Completed
    Last update posted :
    06/01/2023
    Initiation :
    07/08/2014
    Primary completion :
    04/01/2022
    Completion :
    04/15/2022
    EGFR • ALK • EML4 • TP63
    |
    EGFR mutation • ALK fusion • TTF1 negative
    |
    Opdivo (nivolumab) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • Imfinzi (durvalumab) • docetaxel • Talzenna (talazoparib) • Imjudo (tremelimumab-actl) • fexagratinib (ABSK091) • taselisib (GDC-0032) • rilotumumab (AMG 102)
    Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen (Poseidon) (NCT02285179)
    Phase 2
    The Netherlands Cancer Institute
    Completed
    Last update posted :
    10/12/2022
    Initiation :
    11/01/2014
    Primary completion :
    05/01/2022
    Completion :
    05/01/2022
    HER-2 • ER • PGR
    |
    HER-2 overexpression • HER-2 negative • PGR positive
    |
    tamoxifen • taselisib (GDC-0032)
    A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer (NCT01296555)
    Phase 1/2
    Genentech, Inc.
    Completed
    Last update posted :
    09/05/2021
    Initiation :
    03/16/2011
    Primary completion :
    06/25/2021
    Completion :
    06/25/2021
    HER-2 • PIK3CA
    |
    HR positive • HER-2 negative • PIK3CA mutation
    |
    fulvestrant • letrozole • taselisib (GDC-0032)
    PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib (NCT02389842)
    Phase 1
    Royal Marsden NHS Foundation Trust
    Unknown status
    Last update posted :
    11/19/2019
    Initiation :
    03/25/2015
    Primary completion :
    10/31/2018
    Completion :
    01/01/2020
    HER-2 • KRAS • PIK3CA
    |
    KRAS mutation • PIK3CA mutation
    |
    Ibrance (palbociclib) • fulvestrant • pictilisib (GDC-0941) • taselisib (GDC-0032)
    A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) (NCT02273973)
    Phase 2
    Genentech, Inc.
    Completed
    Last update posted :
    05/21/2018
    Initiation :
    11/12/2014
    Primary completion :
    03/13/2017
    Completion :
    03/13/2017
    HER-2 • ER • PIK3CA
    |
    ER positive • HER-2 negative • PIK3CA mutation • PIK3CA wild-type
    |
    letrozole • taselisib (GDC-0032)
    A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer (NCT01862081)
    Phase 1
    Genentech, Inc.
    Completed
    Last update posted :
    11/28/2017
    Initiation :
    07/16/2013
    Primary completion :
    06/09/2017
    Completion :
    06/09/2017
    HER-2
    |
    HER-2 negative
    |
    paclitaxel • docetaxel • taselisib (GDC-0032)